ClinicalTrials.gg
CompletedNCT05384938FASTUpdated Dec 11, 2024Results posted

FAsenra Safety Trial in India

A Phase 4 interventional study of Benralizumab in In Adult Patients of Severe Asthma With Eosinophilic Phenotype in India, sponsored by AstraZeneca. Completed at 13 sites in India. Open to participants aged 18 Years to 75 Years. Per ClinicalTrials.gov, last updated 2024-12-11.

Sponsored by AstraZeneca · Phase 4, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 4
Study type
Interventional
Enrollment
139
Allocation
Not applicable
Ages
18 Years to 75 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 39 studies testing benralizumab in Asthma — 3 open to participants now, 4 under way, 2 of them phase 3. benralizumab · Asthma.

Enrollment
19th of 39
139 · median 128
Started
2021
with 2 others
Phase 4
9 of 39
2 open now
Registered
33rd of 39
by date
Lead sponsor
24 of 39
AstraZeneca

Among the 39 studies testing benralizumab in Asthma, this one is the 19th largest by enrollment, is one of 3 that started in 2021, is one of 9 in phase 4, and was the 33rd registered.

Asthma

4,849 studies on the registry are indexed under Asthma; 605 are open to participants now.

Browse Asthma studies →

Open to participants now

3 of the 39 studies testing benralizumab in Asthma are open now, in 12 countries. Recruiting first, the newest first:

By country, each count listing its studies:

All 3 open studies →

About benralizumab

benralizumab: first FDA approval 2017 (FASENRA), first EMA approval 2018. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 417 Asthma studies recruiting now, 140 (34%) set no upper age limit and 205 (49%) stop at 75 or younger; 147 take children under 18; 105 take healthy volunteers.

This study: 18 Years to 75 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 39 studies testing benralizumab in Asthma, or all of them as a file.
02

Study summary

Benralizumab is a humanised, afucosylated, monoclonal antibody that binds specifically to the human interlukin-5 (IL-5) receptor alpha subunit (IL-5Rα) of target cells such as eosinophils and basophils (Takatsu et al, 1994; Toba et al, 1999; Pelaia et al, 2020).

Benralizumab was generally well tolerated by patients in clinical trials, with no apparent safety concerns.

This study shall be conducted at 10 centers across India. The primary outcome measures will be

  • Percentage of AEs a, SAEs, and TEAEs
  • Nature, incidence, and severity of AEs including unexpected adverse drug reactions
  • Percentage of patients with AEs that lead to study treatment discontinuations.
Read the detailed description

Fasenra (benralizumab) has been recently approved in India with the condition to conduct a Phase 4 postmarketing study in the Indian population, as previous studies did not include patients from India. This prospective postmarketing safety study is planned to meet the regulatory mandate and assess the safety of benralizumab treatment in adult patients of severe asthma with eosinophilic phenotype over a period of 24 weeks. This interventional study will provide insights into the potential risks of eosinophil-lowering therapies when used in routine clinical care in India. The study will also evaluate the effectiveness of benralizumab in reducing asthma exacerbations.

This is a prospective, single-arm, multicentre, interventional, Phase 4 study investigating the safety, tolerability, and effectiveness of Fasenra (benralizumab) in adult patients of severe asthma with eosinophilic phenotype over a period of 24 weeks.

03

Conditions studied

  • In Adult Patients of Severe Asthma With Eosinophilic Phenotype in India

Browse trials for

04

Who can participate

Ages eligible
18 Years to 75 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Male or female patients 18 to 75 years of age inclusive, at the time of signing the
  2. Patients with physician's confirmed diagnosis of severe asthma with an eosinophilic phenotype, ie, a diagnosis of severe asthma in preceding at least 12 months, with an eosinophil count of ≥300 cells/μL at screening, requiring treatment with high-dose ICS (>500 μg fluticasone propionate dry powder formulation, or >800 μg budesonide dry powder formulation, or equivalent total daily dose) and a LABA as maintenance treatment for at least 3 months prior to enrolment
  3. A decreased lung function with prebronchodilator (Pre-BD) (FEV1) of \<80% predicted, demonstrated by spirometry at screening
  4. At least 2 documented asthma exacerbations in the preceeding12 months, except in 30 days before the date of informed consent, that required the use of a systemic or temporary increase from the patient's usual maintenance dose of oral corticosteroid (OCS)
  5. Documented postbronchodilator (post-BD) reversibility in FEV1 of ≥12% and ≥200 mL in FEV1 within 12 months before first dose. If historical documentation is not available, reversibility must be demonstrated and documented at screening or Day 1 before first dose
  6. Benralizumab naïve patients who have not previously received benralizumab prior to the start of this study
  7. Patients who are willing and capable of giving signed informed consent as described in Appendix A, which includes compliance with the requirements and restrictions listed in the informed consent form (ICF) and in this protocol.

Exclusion criteria

Exclusion Criteria:

  1. pulmonary disease other than asthma (eg, active lung infection, , bronchiectasis, pulmonary fibrosis, cystic fibrosis etc.) or ever been diagnosed with pulmonary or systemic disease, other than asthma, that are associated with elevated peripheral eosinophil counts (eg, allergic bronchopulmonary aspergillosis/mycosis, Churg-Strauss syndrome, hypereosinophilic syndrome), which can confound the outcome assessment.
  2. Patients currently enrolled in an interventional clinical study in parallel including those with any biologic treatment
  3. Patients who have received any biologic within 30 days prior to the date of .
  4. Known history of allergy or reaction to the benralizumab formulation or (L-histidine, L-histidine hydrochloride monohydrate, α-trehalose dihydrate, polysorbate 20, water for injection)
  5. History of anaphylaxis to any biologic therapy
  6. A helminth parasitic infection diagnosed within 24 weeks before the date informed consent is obtained that has not been treated with, or has failed to respond to, standard of care therapy
  7. Acute asthma exacerbation 30 days before the date informed consent
  8. Acute asthma exacerbation between screening and first dose of study dose administration.
  9. Acute upper or lower respiratory infections requiring antibiotics or antiviral medication within 30 days before the date informed consent
  10. Patients with within 5 years prior to enrolment, with the exception of adequately treated in-situ carcinoma of the cervix, uteri, basal, or squamous cell carcinoma or non-melanomatous skin cancer with active or recent malignancy
  11. Any clinically significant abnormal findings in physical examination, vital signs, haematology, clinical chemistry, or urinalysis, which, in the opinion of the investigator, may put the participant at risk because of his/her participation in the study
  12. History of current alcohol, drug, or chemical abuse or past abuse that would impair or risk the participant's full participation in the study, in the opinion of the investigator
  13. Female patients who are pregnant or lactating or planning a family during the study period.
Terms in these criteria, in plain language(7)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

FEV1

From a breathing test (spirometry): how much air you can blow out in the first second. Often given as a percentage of what is expected for your age, height and sex.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

COPD

Chronic obstructive pulmonary disease: long-term lung disease that makes it hard to breathe out, including emphysema and chronic bronchitis.

Excipients

The other ingredients in a medicine besides the active drug, such as fillers, colors or preservatives.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

05

Study design

Phase
Phase 4
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
139 participants (actual)

Study arms

  • Other
    Benralizumab

    Single arm, Phase-IV

    Biological: Benralizumab

Interventions

  • BiologicalBenralizumab

    Prospective, Single-arm Study to Assess the Safety of Fasenra® (Benralizumab) in Adult Patients of Severe Asthma with Eosinophilic Phenotype in India

06

What researchers measure

Primary outcomes

  1. Participants With Adverse Events (AEs), Serious AEs, and Treatment-emergent AEs

    The number and percentage of participants who experienced at least one adverse event (AE), serious AE, or treatment-emergent AE experienced are presented

    Time frame: From study treatment to follow-up (up to 24 weeks)

  2. Severity of AEs

    Severity of adverse events (AEs) by intensity grade

    Time frame: From study treatment to follow-up (up to 24 weeks)

  3. Participants With AEs That Led to Study Treatment Discontinuations or Modifications

    Participants with adverse events (AEs) that led to study treatment discontinuations or modifications

    Time frame: From study treatment to follow-up (up to 24 weeks)

Secondary outcomes

  1. Time to First Asthma Exacerbation

    Time to first asthma exacerbation in days in participants with asthma exacerbation

    Time frame: From study treatment to follow-up (up to 24 weeks)

  2. Exacerbation Rate: Before and After Treatment

    The annual exacerbation rate for each participant was calculated by dividing the total number of exacerbations by the number of days participated in the study and multiplying by 365.

    Time frame: From study treatment to follow-up (up to 24 weeks)

  3. Annualized Exacerbation Rate: Overall

    Overall annualized exacerbation rate. The annual exacerbation rate for each participant was calculated by dividing the total number of exacerbations by the number of days participated in the study and multiplying by 365.

    Time frame: From study treatment to follow-up (up to 24 weeks)

  4. Overall Investigators Assessment

    Overall investigator's assessment on the outcome of the treatment: "well controlled", "partly controlled", and "uncontrolled."

    Time frame: From study treatment to follow-up (up to 24 weeks)

  5. Change in Blood Eosinophil Levels From Baseline at Weeks 4, 16, and 24

    Mean change in blood eosinophil levels from baseline at Weeks 4, 16, and 24

    Time frame: Baseline and Weeks 4, 16, and 24

07

Results

Posted Dec 11, 2024

Participant flow

Participant flow — Overall Study
MilestoneBenralizumab
Started139
Completed124
Not completed15
Withdrew: Withdrawal by subject8
Withdrew: Lost to follow-up6
Withdrew: One participant included in study but not included in analysis as did not meet eligibility criteria1

Outcome measures

PrimaryParticipants With Adverse Events (AEs), Serious AEs, and Treatment-emergent AEs

The number and percentage of participants who experienced at least one adverse event (AE), serious AE, or treatment-emergent AE experienced are presented

Time frame:
From study treatment to follow-up (up to 24 weeks)
Reported as:
Count of participants · Participants
Participants With Adverse Events (AEs), Serious AEs, and Treatment-emergent AEs
ParticipantsBenralizumab
Participants with at least one AE (including SAEs)44
Participants with at least one serious AE5
Participants with at least one treatment-emergent AE (including SAEs)43
Participants with at least one non-treatment-emergent and non-serious AE1
PrimarySeverity of AEs

Severity of adverse events (AEs) by intensity grade

Time frame:
From study treatment to follow-up (up to 24 weeks)
Reported as:
Count of participants · Participants
Severity of AEs
ParticipantsBenralizumab
Participants with at least one mild AE33
Participants with at least one moderate AE16
Participants with at least one severe AE1
PrimaryParticipants With AEs That Led to Study Treatment Discontinuations or Modifications

Participants with adverse events (AEs) that led to study treatment discontinuations or modifications

Time frame:
From study treatment to follow-up (up to 24 weeks)
Reported as:
Count of participants · Participants
Participants With AEs That Led to Study Treatment Discontinuations or Modifications
ParticipantsBenralizumab
Participants With AEs That Led to Study Treatment Discontinuations or Modifications0
SecondaryTime to First Asthma Exacerbation

Time to first asthma exacerbation in days in participants with asthma exacerbation

Time frame:
From study treatment to follow-up (up to 24 weeks)
Reported as:
Mean · days
Time to First Asthma Exacerbation
daysBenralizumab
Time to First Asthma Exacerbation112.6 ± 50.45
Statistical analysis
  • Benralizumab · Median time to response: 100.0 · 95% CI 65.00 to 160.0Estimate for Time to Response using Kaplan-Meier method
SecondaryExacerbation Rate: Before and After Treatment

The annual exacerbation rate for each participant was calculated by dividing the total number of exacerbations by the number of days participated in the study and multiplying by 365.

Time frame:
From study treatment to follow-up (up to 24 weeks)
Reported as:
Mean · exacerbations events/year
Exacerbation Rate: Before and After Treatment
exacerbations events/yearBenralizumab
Exacerbation before study2.0 ± 0.00
Exacerbation at end of study0.2 ± 0.47
SecondaryAnnualized Exacerbation Rate: Overall

Overall annualized exacerbation rate. The annual exacerbation rate for each participant was calculated by dividing the total number of exacerbations by the number of days participated in the study and multiplying by 365.

Time frame:
From study treatment to follow-up (up to 24 weeks)
Reported as:
Number · exacerbation events/year
Annualized Exacerbation Rate: Overall
exacerbation events/yearBenralizumab
Annualized Exacerbation Rate: Overall0.36
SecondaryOverall Investigators Assessment

Overall investigator's assessment on the outcome of the treatment: "well controlled", "partly controlled", and "uncontrolled."

Time frame:
From study treatment to follow-up (up to 24 weeks)
Reported as:
Count of participants · Participants
Overall Investigators Assessment
ParticipantsBenralizumab
Well controlled83 (52.72 to 69.72)
Partly controlled45 (25.46 to 41.96)
Uncontrolled7 (2.11 to 10.39)
SecondaryChange in Blood Eosinophil Levels From Baseline at Weeks 4, 16, and 24

Mean change in blood eosinophil levels from baseline at Weeks 4, 16, and 24

Time frame:
Baseline and Weeks 4, 16, and 24
Reported as:
Mean · cells/mm^3
Change in Blood Eosinophil Levels From Baseline at Weeks 4, 16, and 24
cells/mm^3Benralizumab
Week 4 (Visit 2)-511 ± 779.13
Week 16 (Visit 4)-546 ± 867.79
Week 24 (Visit 5)-541 ± 893.62
Statistical analysis
  • Benralizumab · paired t-test · p = <0.0001
  • Benralizumab · paired t-test · p = <0.0001
  • Benralizumab · paired t-test · p = <0.0001

Adverse events

Collected over From screening to follow-up (up to 27 weeks). Non-serious events are listed at a 0% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Benralizumab0/138 (0%)5/138 (3.6%)39/138 (28.3%)
Most frequent serious events
Most frequent serious events
EventBenralizumab
DyspnoeaRespiratory, thoracic and mediastinal disorders4/138
Productive coughRespiratory, thoracic and mediastinal disorders4/138
PyrexiaGeneral disorders3/138
H1n1 influenzaInfections and infestations1/138
Back painMusculoskeletal and connective tissue disorders1/138
ConstipationGastrointestinal disorders1/138
Most frequent other events
Showing 10 of 26
Most frequent other events
EventBenralizumab
PyrexiaGeneral disorders20/138
CoughRespiratory, thoracic and mediastinal disorders4/138
NasopharyngitisInfections and infestations3/138
DyspnoeaRespiratory, thoracic and mediastinal disorders3/138
HeadacheNervous system disorders2/138
ParaesthesiaNervous system disorders2/138
HaemoptysisRespiratory, thoracic and mediastinal disorders2/138
Productive coughRespiratory, thoracic and mediastinal disorders2/138
Gastrooesophageal reflux diseaseGastrointestinal disorders2/138
AstheniaGeneral disorders2/138

Baseline characteristics

Age, Continuous
Age, Continuous(Years)Benralizumab
Mean47.7 ± 14.3
Sex: Female, Male
Sex: Female, Male(Participants)Benralizumab
Female71
Male67
Race/Ethnicity, Customized
Race/Ethnicity, Customized(Participants)Benralizumab
ASIAN138
OTHER0
Female, Indicate childbearing potential
Female, Indicate childbearing potential(Participants)Benralizumab
Premenarchal0
Premenopausal female6
Postmenopausal female30
Potentially able to bear children35
08

Study locations

13 sites
  • Research Site
    Bengaluru, 560099, India
  • Research Site
    Chennai, 600035, India
  • Research Site
    Delhi, 110029, India
  • Research Site
    Hyderabad, 500084, India
  • Research Site
    Jaipur, 302039, India
  • Research Site
    Jodhpur, 342005, India
  • Research Site
    Luknow, 226003, India
  • Research Site
    Mumbai, 400008, India
  • Research Site
    New Delhi, 110060, India
  • Research Site
    Noida, 201 301, India
  • Research Site
    Noida, 201301, India
  • Research Site
    Noida, 201304, India
  • Research Site
    Vishakhapatnam, 530002, India
09

References and documents

Related links

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Nov 2021 to primary completion in Jul 2023, 19 months.

Results were first posted in Dec 2024, 1 year 5 months after primary completion.

Of 66 industry-sponsored phase 4 interventional studies under Asthma, half reached primary completion within 21 months of starting (the median), counting those still running; a quarter within 9 and three quarters within 33. This study's 19 months is close to that.

Counting every sponsor, half of 156 studies reached it within 24 months; a quarter within 11 and three quarters within 37.

How these figures are worked out, and which studies are left out of them.

Registered
Nov 9, 2021
First posted
May 20, 2022
StartActual
Nov 19, 2021
Primary completionActual
Jul 1, 2023
CompletionActual
Jul 1, 2023
Results first posted
Dec 11, 2024
Last update
Dec 11, 2024
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Dec 11, 2024, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT05384938
Lead sponsor
AstraZeneca
Responsible party
Sponsor
First posted
May 20, 2022
Start date
Nov 19, 2021
Primary completion
Jul 1, 2023
Completion
Jul 1, 2023
Results posted
Dec 11, 2024
Last update
Dec 11, 2024

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Oct 2024. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Benralizumab

Start the discussion